Olumiant and Platelet count increased - a phase IV clinical study of FDA data

Summary:

Platelet count increased is reported as a side effect among people who take Olumiant (baricitinib), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Pantoprazole, and have Alopecia areata.

The phase IV clinical study analyzes which people have Platelet count increased when taking Olumiant. It is created by eHealthMe based on reports of 5,692 people who have side effects when taking Olumiant from the FDA, and is updated regularly.

What is Olumiant?

Olumiant has active ingredients of baricitinib. eHealthMe is studying from 5,698 Olumiant users. Check the latest studies of Olumiant.

What is Platelet count increased?

Platelet count increased is found to be associated with 958 drugs and 1,190 conditions by eHealthMe. Check the latest studies of Platelet count increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

5,692 people reported to have side effects when taking Olumiant.
Among them, 13 people (0.23%) have Platelet count increased.

Could Olumiant cause Platelet count increased?

Among these 13 people:

How long have people been on Olumiant when they have Platelet count increased? *

What is the gender of people who have Platelet count increased when taking Olumiant? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Platelet count increased when taking Olumiant? *

What are other drugs people take besides Olumiant? *

Pantoprazole: 1 person, 7.69%

What are other side effects people have besides Platelet count increased? *

White Blood Cell Count Increased: 1 person, 7.69%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 7.69%
Meningoencephalitis Herpetic (inflammation of the brain and meninges by virus): 1 person, 7.69%
Lipids Increased (excess lipid in body): 1 person, 7.69%
Immunoglobulins Abnormal: 1 person, 7.69%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 7.69%
Eosinophil Count Increased: 1 person, 7.69%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 7.69%
Anaemia (lack of blood): 1 person, 7.69%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 7.69%

What are the existing conditions these people have? *

Alopecia Areata (patchy baldness that typically begins with rapid hair loss): 6 people, 46.15%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 23.08%
Hair Loss: 1 person, 7.69%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Olumiant and have Platelet count increased?

- Check whether Platelet count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olumiant:

Olumiant (5,698 reports)

Browse all side effects of Olumiant:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Platelet count increased:

Platelet count increased (958 drugs)

Browse all the conditions that are associated with Platelet count increased:

Platelet count increased (1,190 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on baricitinib (the active ingredients of Olumiant) and Olumiant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.